ASTRAZENECA PLC CEDEAR EACH REP 0.5 ADR USD0.25ASTRAZENECA PLC CEDEAR EACH REP 0.5 ADR USD0.25ASTRAZENECA PLC CEDEAR EACH REP 0.5 ADR USD0.25

ASTRAZENECA PLC CEDEAR EACH REP 0.5 ADR USD0.25

No trades
See on Supercharts

Key facts today

AstraZeneca's Calquence, a BTK inhibitor launched in 2017, competes with BeiGene's Brukinsa from 2019. The BTK inhibitor market is expected to grow significantly.
Analyze the impactAnalyze the impact
Market capitalization
‪233.67 T‬ARS
564.758ARS
‪1.75 T‬ARS
‪13.49 T‬ARS
Beta (1Y)
0.37

About ASTRAZENECA PLC ORD USD0.25


CEO
Pascal Soriot
Headquarters
Cambridge
Employees (FY)
‪89.9 K‬
Founded
1992
ISIN
ARDEUT112489
FIGI
BBG000DDG785
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy